Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Heart Failure with Preserved Ejection Fraction (Capacity HFpEF): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

James E. Udelson; Gregory D. Lewis; Sanjiv J. Shah; Michael R. Zile; Margaret M. Redfield; John Burnett; John D. Parker; Jelena Seferovic; Phebe J. Wilson; Robert S. Mittleman; Albert T. Profy; Marvin A. Konstam

doi:10.1016/j.cardfail.2020.09.030

Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Heart Failure with Preserved Ejection Fraction (Capacity HFpEF): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2020.09.030 ◽

2020 ◽

Vol 26 (10) ◽

pp. S8

Author(s):

James E. Udelson ◽

Gregory D. Lewis ◽

Sanjiv J. Shah ◽

Michael R. Zile ◽

Margaret M. Redfield ◽

...

Keyword(s):

Heart Failure ◽

Soluble Guanylate Cyclase ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Patients With Heart Failure ◽

Soluble Guanylate Cyclase Stimulator

Download Full-text

Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)

American Heart Journal ◽

10.1016/j.ahj.2020.01.009 ◽

2020 ◽

Vol 222 ◽

pp. 183-190 ◽

Cited By ~ 5

Author(s):

James E. Udelson ◽

Gregory D. Lewis ◽

Sanjiv J. Shah ◽

Michael R. Zile ◽

Margaret M. Redfield ◽

...

Keyword(s):

Heart Failure ◽

Soluble Guanylate Cyclase ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Patients With Heart Failure ◽

Soluble Guanylate Cyclase Stimulator

Download Full-text

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(14)70209-1 ◽

2014 ◽

Vol 13 (11) ◽

pp. 1100-1107 ◽

Cited By ~ 225

Author(s):

David W Dodick ◽

Peter J Goadsby ◽

Stephen D Silberstein ◽

Richard B Lipton ◽

Jes Olesen ◽

...

Keyword(s):

Episodic Migraine ◽

Calcitonin Gene Related Peptide ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Phase 2 Trial ◽

Calcitonin Gene

Download Full-text

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

The Lancet ◽

10.1016/s0140-6736(11)61126-4 ◽

2011 ◽

Vol 378 (9792) ◽

pp. 676-683 ◽

Cited By ~ 216

Author(s):

John GF Cleland ◽

John R Teerlink ◽

Roxy Senior ◽

Evgeny M Nifontov ◽

John JV Mc Murray ◽

...

Keyword(s):

Heart Failure ◽

Cardiac Function ◽

Systolic Heart Failure ◽

Phase 2 ◽

Cardiac Myosin ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Omecamtiv Mecarbil ◽

Dose Ranging

Download Full-text

SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial

10.1136/annrheumdis-2018-eular.2727 ◽

2018 ◽

Author(s):

R. Fleischmann ◽

H. Bliddal ◽

F. Blanco ◽

T. Schnitzer ◽

C. Peterfy ◽

...

Keyword(s):

Knee Osteoarthritis ◽

Interleukin 1 ◽

Dual Variable ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Parallel Group ◽

Alpha Beta

Download Full-text

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30192-2 ◽

2016 ◽

Vol 15 (11) ◽

pp. 1148-1159 ◽

Cited By ~ 28

Author(s):

Ludwig Kappos ◽

Douglas L Arnold ◽

Amit Bar-Or ◽

John Camm ◽

Tobias Derfuss ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Relapsing Multiple Sclerosis

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.720592850.793525445 ◽

2016 ◽

Author(s):

Mark Obermann ◽

Dagny Holle

Keyword(s):

Episodic Migraine ◽

Calcitonin Gene Related Peptide ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Phase 2 Trial ◽

Calcitonin Gene

Download Full-text

Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30196-x ◽

2016 ◽

Vol 15 (11) ◽

pp. 1160-1169 ◽

Cited By ~ 99

Author(s):

Kevin N Sheth ◽

Jordan J Elm ◽

Bradley J Molyneaux ◽

Holly Hinson ◽

Lauren A Beslow ◽

...

Keyword(s):

Phase 2 ◽

Brain Swelling ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Hemispheric Infarction

Download Full-text

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)00019-3 ◽

2016 ◽

Vol 15 (4) ◽

pp. 382-390 ◽

Cited By ~ 187

Author(s):

Hong Sun ◽

David W Dodick ◽

Stephen Silberstein ◽

Peter J Goadsby ◽

Uwe Reuter ◽

...

Keyword(s):

Episodic Migraine ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial

Download Full-text

1073-P: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease

Diabetes ◽

10.2337/db20-1073-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1073-P

Author(s):

JOHN P. HANRAHAN ◽

IAN DE BOER ◽

GEORGE BAKRIS ◽

PHEBE WILSON ◽

JAMES D. WAKEFIELD ◽

...

Keyword(s):

Kidney Disease ◽

Guanylate Cyclase ◽

Diabetic Kidney Disease ◽

Soluble Guanylate Cyclase ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Diabetic Kidney ◽

Double Blind Placebo ◽

Soluble Guanylate Cyclase Stimulator

Download Full-text

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30399-4 ◽

2017 ◽

Vol 16 (3) ◽

pp. 208-216 ◽

Cited By ~ 26

Author(s):

Vincent Meininger ◽

Angela Genge ◽

Leonard H van den Berg ◽

Wim Robberecht ◽

Albert Ludolph ◽

...

Keyword(s):

Amyotrophic Lateral Sclerosis ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Lateral Sclerosis

Download Full-text